Bruker (BRKR)
(Delayed Data from NSDQ)
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Zacks News
Here's Why Momentum Investors Will Love Bruker (BRKR)
by Zacks Equity Research
Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bruker (BRKR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Bruker (BRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Looking for a Growth Stock? 3 Reasons Why Bruker (BRKR) is a Solid Choice
by Zacks Equity Research
Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 16.67% and 1.45%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scientific Instruments Industry Outlook: Prospects Look Bright
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is benefiting from solid prospects in emerging markets, robust end-market demand and increasing spending on health care.
Top Ranked Growth Stocks to Buy for April 11th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, April 11th.
Top Ranked Growth Stocks to Buy for April 10th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, April 10th.
Top Ranked Growth Stocks to Buy for April 8th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 8th.
Are You Looking for a Top Momentum Pick? Why Bruker (BRKR) is a Great Choice
by Zacks Equity Research
Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Growth Stocks to Buy for March 29th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, March 29th.
Is Bruker (BRKR) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.
Bruker Consistently Gains From NANO & New Strategic Buyouts
by Zacks Equity Research
Bruker (BRKR) is progressing well with its three strategic buyouts, indicative of a majority interest in both Hain Diagnostics and Mestrelab along with the Alicona Imaging acquisition.
Top Ranked Growth Stocks to Buy for March 27th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, March 27th.
Top Ranked Growth Stocks to Buy for March 26th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, March 26th.
Top Ranked Growth Stocks to Buy for March 21st
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 21st
Why Is Bruker (BRKR) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here is Why Growth Investors Should Buy Bruker (BRKR) Now
by Zacks Equity Research
Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.
Top Ranked Growth Stocks to Buy for March 4th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 4th
Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts
by Zacks Equity Research
Bruker's (BRKR) CALID and NANO groups hold promise.
Bruker (BRKR) Upgraded to Buy: Here's Why
by Zacks Equity Research
Bruker (BRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong
by Zacks Equity Research
Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.
Bruker (BRKR) Meets Q4 Earnings Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 0.00% and 1.67%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Bruker (BRKR) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks.com featured expert Kevin Matras highlights: Crocs, Novanta, Abercrombie & Fitch and Bruker
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Crocs, Novanta, Abercrombie & Fitch and Bruker